The most serious kind of viral hepatitis is hepatitis B virus (HBV). In China, there are 87 million persons who are chronic HBV carriers. People who have been infected with HBV for a long period are more likely to develop HBV-related liver diseases. In this paper, we examine differences in two variables (hepatitis B antibody rate and screening rate) between countries, taking into account social factors and prevailing transmission factors, and propose governance recommendations that are consistent with China's national situation. We draw on the public health governance of relevant countries and refer to WHO governance strategies. First, regulate the primary transmission channels, interrupt mother-to-child transmission, then apply viral interruption in newborns in less developed areas, to create a demographic faultage of the virus. Second, to limit transmission rates and preserve liver health, combine medical resources and encourage people to take free immunizations and antiviral therapy.

Dongjian Xu. An Investigation of Hepatitis B Infection in China. International Journal of Frontiers in Medicine (2022), Vol. 4, Issue 6: 57-60. https://doi.org/10.25236/IJFM.2022.040610.

[1] Ott, J. J., Stevens, G. A. and Wiersma, S. T. (2012) “The risk of perinatal hepatitis B virus transmission: hepatitis B e antigen (HBeAg) prevalence estimates for all world regions,” BMC infectious diseases, 12(1), p. 131.

[2] André, F. (2000) “Hepatitis B epidemiology in Asia, the Middle East and Africa,” Vaccine, 18, pp. S20–S22.

[3] Information on:Hepatitis B - chapter 4 - 2020 Yellow Book (no date) Cdc.gov. Available at: https://wwwnc.cdc.gov/travel/yellowbook/2020/travel-related-infectious-diseases/hepatitis-b(Accessed: October 8, 2021).

[4] Chang, M.-L. and Liaw, Y.-F. (2014) “Hepatitis B flares in chronic hepatitis B: pathogenesis, natural course, and management,” Journal of hepatology, 61(6), pp. 1407–1417.

[5] Schweitzer, A. et al. (2015) “Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013,” Lancet, 386(10003), pp. 1546–1555.

[6] Peng, S. (2020) “HBV transmission route among children in China. A letter in response to Young Chinese children without seroprotective hepatitis B surface antibody could be at risk of hepatitis B virus infection through horizontal transmission,” Journal of viral hepatitis, 27(4), p. 461.

[7] Xin, X. et al. (2016) “Seroepidemiological survey of hepatitis B virus infection among 764,460 women of childbearing age in rural China: A cross-sectional study,” Journal of clinical virology: the official publication of the Pan American Society for Clinical Virology, 81, pp. 47–52.

[8] Hu, Y. et al. (2012) “Gaps in the prevention of perinatal transmission of hepatitis B virus between recommendations and routine practices in a highly endemic region: a provincial population-based study in China,” BMC infectious diseases, 12(1), p. 221.

[9] Wang, H. et al. (2019) “Hepatitis B infection in the general population of China: a systematic review and meta-analysis,” BMC infectious diseases, 19(1), p. 811.

[10] Childs, L., Roesel, S. and Tohme, R. A. (2018) “Status and progress of hepatitis B control through vaccination in the South-East Asia Region, 1992–2015,” Vaccine, 36(1), pp. 6–14.

[11] Shepard, C.W. et al., (2006). Hepatitis B Virus Infection: Epidemiology and Vaccination. Epidemiologic reviews, 28(1), pp.112–125.

[12] Xia, G. et al. (1996) “Prevalence of hepatitis B and C virus infections in the general Chinese population. Results from a nationwide cross-sectional seroepidemiologic study of hepatitis A, B, C, D, and E virus infections in China, 1992,” International hepatology communications, 5(1), pp. 62–73.

[13] Willis, B. C. et al. (2010) “Gaps in hospital policies and practices to prevent perinatal transmission of hepatitis B virus,” Pediatrics, 125(4), pp. 704–711.

[14] Cui, F. et al. (2013) “Reprint of: Factors associated with effectiveness of the first dose of hepatitis B vaccine in China: 1992-2005,” Vaccine, 31 Suppl 9, pp. J56-61.

[15] Liang, X. et al., (2009). Epidemiological serosurvey of Hepatitis B in China—Declining HBV prevalence due to Hepatitis B vaccination. Vaccine, 27(47), pp.6550–6557.

[16] Liu, J. et al. (2019) “Countdown to 2030: eliminating hepatitis B disease, China,” Bulletin of the World Health Organization, 97(3), pp. 230–238. doi: 10.2471/BLT.18.219469.

[17] Chida, Y., Sudo, N. and Kubo, C. (2006) “Does stress exacerbate liver diseases?,” Journal of gastroenterology and hepatology, 21(1 Pt 2), pp. 202–208. doi: 10.1111/j.1440-1746.2006.04110.x.